FARXIGA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6414126 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(3 years ago) | |
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(1 year, 5 months from now) | |
| US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9198925 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct, 2020
(3 years ago) | |
| US6936590 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(3 years ago) | |
| US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(8 days ago) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(11 months from now) | |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(11 months from now) | |
| US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(1 year, 2 months from now) | |
| US8329648 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(2 years from now) | |
| US8906851 | ASTRAZENECA AB | Method for treating diabetes |
Aug, 2026
(2 years from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(3 years from now) | |
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8221786 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US7851502 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Aug, 2028
(4 years from now) | |
| US8721615 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(5 years from now) | |
| US8685934 | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
May, 2030
(6 years from now) | |
| US11826376 | ASTRAZENECA AB | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same |
Jul, 2039
(15 years from now) | |
| US10973836 | ASTRAZENECA AB | Methods of treating heart failure with reduced ejection fraction |
Mar, 2040
(15 years from now) | |
Farxiga is owned by Astrazeneca Ab.
Farxiga contains Dapagliflozin.
Farxiga has a total of 20 drug patents out of which 4 drug patents have expired.
Expired drug patents of Farxiga are:
- US9198925
- US6936590
- US9238076
- US6414126
Farxiga was authorised for market use on 08 January, 2014.
Farxiga is available in tablet;oral dosage forms.
Farxiga can be used as treatment of type 2 diabetes mellitus, treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone, reduce the risk of cardiovascular death and hospitalization for heart failure and urgent heart failure visits in adults with heart failure with preserved ejection fraction and without type ii diabetes, reducing fasting plasma glucose in a human in need thereof in combination with a sustained-release composition containing exendin-4, reduction of the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction and without type ii diabetes, treatment of type 2 diabetes mellitus in combination with exenatide.
Drug patent challenges can be filed against Farxiga from 08 January, 2018.
The generics of Farxiga are possible to be released after 09 March, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-857) | Apr 30, 2024 |
| M(M-298) | May 08, 2026 |
| M(M-238) | Feb 22, 2022 |
| New Indication(I-834) | May 05, 2023 |
| M(M-212) | Oct 20, 2020 |
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-157) | Mar 11, 2018 |
| New Indication(I-841) | Oct 18, 2022 |
Drugs and Companies using
DAPAGLIFLOZIN ingredient
NCE-1 date:
Market Authorisation Date:
08 January, 2014Treatment:
Treatment of type 2 diabetes mellitus in combination with exenatide; Treatment of type 2 diabetes mellitus; Reducing fasting plasma glucose in a human in need thereof in combination with a sustained-r...Dosage:
How can I launch a generic of FARXIGA before its drug patent expiration?
More Information on Dosage
FARXIGA family patents
